Respiratory Syncytial Virus (RSV) is the most commonly occurring lower respiratory tract viral infection in young children and usually isn’t serious, but in premature infants and babies under six months old, the infection can be severe, and even fatal.

There is no vaccine, but there is a biologic drug — an antibody against the virus, called Palivizumab — that is used to help prevent RSV infections in preemies born before 29 weeks of gestation, but half the treated infants still end up in the hospital with an RSV infection.

And there are several other problems with Palivizumab: Doctors only… more

Go to Source


Comments are closed.